| 纯度 | > 80 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADAL |
| Uniprot No | Q6DHV7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-267aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSEFMIEAEEQQPCKTDFYSELPKVELHA HLNGSISSHTMKKLIAQKPDLKIHDQMTVIDKGKKRTLEECFQMFQTIHQ LTSSPEDILMVTKDVIKEFADDGVKYLELRSTPRRENATGMTKKTYVESI LEGIKQSKQENLDIDVRYLIAVDRRGGPLVAKETVKLAEEFFLSTEGTVL GLDLSGDPTVGQAKDFLEPLLEAKKAGLKLALHLSEIPNQKKETQILLDL LPDRIGHGTFLNSGEGGSLDLVDFVRQHRIPLGKAWSFRSSR |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADAL重组蛋白的3篇参考文献示例(注：部分内容为模拟，实际文献需通过学术数据库验证)：
---
1. **文献名称**：*Expression and Functional Analysis of Recombinant ADAL Protein in Bacterial Systems*
**作者**：Zhang, Y. et al.
**摘要**：研究报道了ADAL重组蛋白在大肠杆菌中的高效表达与纯化，并通过酶活实验证实其具有腺苷脱氨酶活性，为后续疾病治疗研究奠定基础。
2. **文献名称**：*Structural Insights into Recombinant ADAL Protein: Implications for Substrate Specificity*
**作者**：Lee, S. & Kim, H.
**摘要**：利用X射线晶体学解析ADAL重组蛋白的三维结构，揭示其底物结合域的关键氨基酸残基，解释了其对特定核苷类似物的催化机制。
3. **文献名称**：*Therapeutic Potential of Recombinant ADAL in Autoimmune Disorders*
**作者**：Müller, R. et al.
**摘要**：在小鼠模型中验证ADAL重组蛋白通过调节细胞外腺苷水平抑制过度免疫反应，提示其在治疗类风湿性关节炎等疾病中的潜在应用。
---
**提示**：若需具体文献，建议在PubMed或Google Scholar中检索“recombinant ADAL protein”或结合ADAL的全称(如Adenosine Deaminase-Like Protein)精确查询。部分研究可能以“重组腺苷脱氨酶”为关键词，需结合研究背景筛选。
ADAL (Adenosine Deaminase-Like) recombinant protein is a engineered version of the adenosine deaminase enzyme family, which plays critical roles in purine metabolism and immune function. Naturally occurring adenosine deaminases catalyze the irreversible deamination of adenosine to inosine, regulating cellular adenosine levels and supporting lymphocyte maturation. The ADAL variant shares structural and functional similarities with the well-characterized ADA enzyme but exhibits distinct substrate preferences or regulatory properties, making it a subject of interest in biochemical and therapeutic research.
Recombinant ADAL is produced through genetic engineering techniques, where the ADAL gene is cloned into expression vectors (e.g., bacterial, yeast, or mammalian systems) to enable large-scale production. This approach ensures high purity, consistency, and scalability compared to tissue-derived enzymes. Common purification methods include affinity chromatography (e.g., His-tag systems) followed by rigorous quality control assessments (e.g., SDS-PAGE, activity assays).
Therapeutic applications focus on enzyme replacement therapy (ERT) for disorders like ADA-deficient severe combined immunodeficiency (ADA-SCID), where mutations in the ADA gene impair immune cell development. Recombinant ADAL’s potential to modulate adenosine levels also links it to inflammatory and neurological conditions. In biotechnology, it serves as a tool for studying nucleotide metabolism, protein engineering, and drug screening. Additionally, its stability and catalytic efficiency can be enhanced through site-directed mutagenesis, expanding its utility in industrial biocatalysis.
Safety and efficacy profiles are rigorously evaluated to meet clinical standards, positioning recombinant ADAL as a versatile candidate for both biomedical and research applications.
×
